The patent war with Big Pharma

Back    Forward

Major pharmaceutical companies have recently locked horns with Indian courts over the issue of patents. India has conformed with international patent regulations, but is negotiating aggressively to defend its own drug industry, which produces excellent generic medicines used in many developing countries.

India’s Supreme Court has definitively rejected Swiss pharmaceutical giant Novartis AG’s request to recognise the patent on its drug Glivec (known in the US as Gleevec), a medicine widely used in the treatment of leukaemia.

Indian drug companies are now free to legally produce and distribute generic versions of the medicine, with an immediate economic
impact for roughly 300,000 cancer patients in the country.

To continue reading download free pdf.

Continue reading this article and all other Eastwest and content.

Subscribe for 1 year and gain unlimited access to all content on plus both the digital and the hard copy of the geopolitical magazine for € 45, or gain 1 year of unlimited access to only the website and digital magazine for € 20


La voce
dei Lettori

eastwest risponderà ogni settimana ai commenti sui social e alle domande inviate dai lettori. Potete far pervenire la vostra domanda usando il tasto qui sotto. Per essere pubblicati, i contributi devono essere firmati con nome, cognome e città Invia la tua domanda ad eastwest